Department of Radiation Oncology and MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lancet Oncol. 2015 Nov;16(15):e568-e576. doi: 10.1016/S1470-2045(15)00146-1.
Through the concerted efforts of many patients, health-care providers, legislators, and other supporters, the past decade has seen the development of the first clinics dedicated to the care of patients with inflammatory breast cancer in the USA and other countries. Together with social networking, advocacy, and education, a few specialised centres have had substantial increases in patient numbers (in some cases ten times higher), which has further expanded the community of science and advocacy and increased the understanding of the disease process. Although inflammatory breast cancer is considered rare, constituting only 2-4% of breast cancer cases, poor prognosis means that patients with the disease account for roughly 10% of breast cancer mortality annually in the USA. I propose that the unique presentation of inflammatory breast cancer might require specific, identifiable changes in the breast parenchyma that occur before the tumour-initiating event. This would make the breast tissue itself a tumour-promoting medium that should be treated as a component of the pathology in multidisciplinary treatment and should be further studied for complementary targets to inhibit the pathobiology that is specific to inflammatory breast cancer.
在许多患者、医疗保健提供者、立法者和其他支持者的共同努力下，过去十年中，美国和其他国家出现了首批专门为炎性乳腺癌患者提供护理的诊所。通过社交网络、宣传和教育，一些专门的中心的患者数量显著增加（在某些情况下增加了十倍），这进一步扩大了科学界和宣传界的规模，增加了对疾病过程的了解。虽然炎性乳腺癌被认为是罕见的，仅占乳腺癌病例的 2-4%，但预后不良意味着在美国，每年约有 10%的乳腺癌死亡患者患有这种疾病。我提出，炎性乳腺癌的独特表现可能需要在肿瘤起始事件之前发生在乳腺实质中的特定、可识别的变化。这将使乳腺组织本身成为一种促进肿瘤的介质，应该将其视为多学科治疗中病理学的一个组成部分，并进一步研究针对炎性乳腺癌特有的病理生物学的补充靶点。
